One-Time Cell Therapy Amtagvi Gets Accelerated Approval for Advanced Melanoma

Amtagvi is a tumor-derived autologous T cell immunotherapy designed to deploy patient-specific T cells called TIL cells to locate and attack cancer cells.

Related Keywords

Alexandern Shoushtari , ,Drug Administration ,Boxed Warning ,Melanoma Oncologist ,Cellular Therapist ,Memorial Sloan Kettering Cancer ,